Aeglea BioTherapeutics, Inc./$SYRE

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Aeglea BioTherapeutics, Inc.

Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

Ticker

$SYRE
Sector
Primary listing

Employees

87

SYRE Metrics

BasicAdvanced
$945M
-
-$2.85
2.83
-

Bulls say / Bears say

Strong cash runway supports development, with $526.6 million in cash, cash equivalents, and marketable securities as of June 30, 2025, expected to fund the company into the second half of 2028 (Globe Newswire).
Advancing pipeline with the start of the Phase 2 SKYLINE-UC platform trial for ulcerative colitis and an on-schedule Q3 launch of the Phase 2 SKYWAY-RD basket study for rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis, setting up the company for up to nine proof-of-concept readouts over the next two years (Globe Newswire).
Interim Phase 1 results for two next-generation TL1A antibodies show strong tolerability, pharmacokinetics supporting quarterly or twice-yearly dosing, and full target engagement for 20 weeks, highlighting Spyre’s potential to deliver best-in-class TL1A inhibitors in IBD and rheumatic diseases (Globe Newswire).
Data summarised monthly by Lightyear AI. Last updated on 3 Sept 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $SYRE

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs